Zai Lab (ZLAB)

• Market cap: $3.9B
• 1 day: -2.88%
• 5 days: -4.09%
• 1 month: -8.45%
• 3 months: 9.70%
• 6 months: 0.35%
• Year to date: 37.16%
• 1 year: 78.82%
• 5 years: -58.47%
• 10 years: 21.84%
• Sector: Healthcare
• Industry: Biotechnology

About: Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

Employees: 1,844

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

33.17% more ownership

Funds ownership: 5.15% [Q1] → 38.32% (+33.17%) [Q2]

3% less first-time investments, than exits

New positions opened: 33 | Existing positions closed: 34

4% less funds holding

Funds holding: 158 [Q1] → 152 (-6) [Q2]

16% less repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 57

24% less capital invested

Capital invested by funds: $1.97B [Q1] → $1.49B (-$481M) [Q2]

29% less funds holding in top 10

Funds holding in top 10: 7 [Q1] → 5 (-2) [Q2]

59% less call options, than puts

Call options by funds: $2.76M | Put options by funds: $6.68M

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $69 103% upside
• Avg. target: $72 112% upside
• High target: $75 120% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Citigroup Yigal Nochomovitz	103% upside $69	Buy Maintained	11 Aug 2025
Leerink Partners Jonathan Chang	120% upside $75	Outperform Maintained	30 Jun 2025